This is to inform you that Outcome of the Board Meeting of the Company held on today i.e. Thursday 14th May 2026 in accordance with SEBl (Listing Obligations and Disclosures Requirements) ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 14.3 pts more than Nifty Microcap 250 and 14.5 pts more than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biogen Pharmachem Industries Ltd reported strong audited results for FY26 with revenue surging to Rs. 255.80 lakhs from Rs. 83.84 lakhs in FY25, representing approximately 205% year-on-year growth. The company turned profitable with PBT of Rs. 95.67 lakhs (vs loss of Rs. 29.27 lakhs in prior year) and PAT of Rs. 85.95 lakhs. The Q4 standalone quarter showed a loss of Rs. 35.88 lakhs on revenue of Rs. 57.82 lakhs. Total assets stood at Rs. 9,939.89 lakhs with equity of Rs. 9,908.71 lakhs. The statutory auditor issued an Unmodified Opinion (clean audit report) confirming true and fair view of financials. Share capital increased to Rs. 9,026.03 lakhs post a Rs. 630 lakh share issuance during the year.
The company showed exceptional revenue growth but profitability was heavily weighted to the first three quarters with Q4 posting a loss. The clean audit opinion provides assurance on financial integrity despite the Q4 loss trend.